Our results concerning CBL0137 effects on DNMT3A and BET family proteins are supported by recent data from Xiao et al., who showed a synergistic effect of CBL0137 and Panobinostat, an FDA-approved HDAC inhibitor, in a MYCN-amplified neuroblastoma model [42]. The gene discussed is MYCN; the disease is neuroblastoma.